Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000132

EU PAS number

EUPAS1000000132

Study ID

1000000132

Official title and acronym

Fezolinetant Experience for the Treatment of Vasomotor Symptoms Associated with Menopause Among Women in a German Real-life Setting

DARWIN EU® study

No

Study countries

Germany

Study description

This study is for women in Germany who are going through menopause.
They have symptoms including hot flashes and night sweats (also called vasomotor symptoms). Their doctor has decided to give them fezolinetant tablets to help treat these symptoms.
Fezolinetant tablets do not contain hormones. Fezolinetant tablets have been approved in some countries to treat hot flashes and night sweats.

Study status

Ongoing
Research institutions and networks

Institutions

Astellas Pharma Europe Ltd.

Contact details

Regina Schaetzle

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Astellas Pharma Europe Ltd.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable